Xencor (XNCR) Price & Analysis

Compare

336 Followers

XNCR Stock Chart & Stats

$14.00

-$0.21(-0.88%)

At close: Jan 08 4:00 PM EST

$14.00

-$0.21(-0.88%)

Day’s Range― - ―

52-Week Range$6.92 - $27.24

Previous CloseN/A

Volume126.93K

Average Volume (3M)1.33M

Market Cap

$1.02B

Enterprise Value$352.92M

Total Cash (Recent Filing)$386.78M

Total Debt (Recent Filing)$69.27M

Price to Earnings (P/E)―

Beta1.70

Next Earnings

Mar 04, 2026

EPS Estimate

-0.62

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.08

Shares Outstanding71,323,044

10 Day Avg. Volume1,564,719

30 Day Avg. Volume1,334,755

Financial Highlights & Ratios

PEG Ratio-0.09

Price to Book (P/B)2.21

Price to Sales (P/S)13.53

P/FCF Ratio-7.18

Enterprise Value/Market Cap0.34

Enterprise Value/Revenue2.41

Enterprise Value/Gross Profit3.92

Enterprise Value/Ebitda-4.85

Forecast

1Y Price Target

$24.00

Price Target Upside71.43% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering11

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessXencor presented initial Phase I dose-escalation data with the ENPP3xCD3 bispecific T-cell engager XmAb819 in clear cell renal cell carcinoma, demonstrating a promising initial profile with a 25% overall response rate.

Financial PositionXencor is well-capitalized to reach its next value inflection point, suggesting strong financial positioning for future developments.

Pipeline And DevelopmentThe initiation of the Phase IIb XENITH-UC trial for XmAb942 in ulcerative colitis is highlighted as progress from the quarter.

Bears Say

Dosing IssuesA dosing-preparation error in early 2025 led to higher priming exposures in ~25% of patients, resulting in more severe CRS and delayed therapeutic dosing.

Safety ConcernsThe overall safety profile is clouded by 18 patients with priming dose prep errors.

Treatment DiscontinuationA high rate of treatment discontinuation (75%, 55% from progressive disease) will remain a point to watch during dose expansion.

Xencor News

Xencor price target raised to $42 from $40 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Xencor (XNCR) to $42 from $40 and keeps an Overweight...

2d ago

XNCR

Xencor price target lowered to $18 from $20 at JPMorgan

JPMorgan lowered the firm’s price target on Xencor (XNCR) to $18 from $20 and keeps an Overweight rating...

2d ago

XNCR

Xencor reports Q3 EPS (8c), consensus (70c)

Reports Q3 revenue $21.0M, consensus $28.7M. “Xencor’s (XNCR) two novel, first-in-class, CD3 T-cell engaging bispecific antibodies, XmAb819 and...

2d ago

XNCR

Beaten Down by 35%-Plus: Analysts Say These 2 Oversold Stocks Are Poised to Turn the Corner

The stock markets have been ripping this year, with investors buying into the bullish trend. However, some savvy...

4d ago

GKOS

XNCR

Xencor upgraded to Overweight from Underweight at Barclays

Barclays analyst Etzer Darout double upgraded Xencor (XNCR) to Overweight from Underweight with a price target of $23,...

10d ago

XNCR

Xencor price target raised to $15 from $14 at BofA

BofA raised the firm’s price target on Xencor (XNCR) to $15 from $14 and keeps a Neutral rating...

12d ago

XNCR

Xencor presents initial data for XmAb819

On Friday, the company announced: “Xencor (XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of...

12d ago

XNCR

Xencor price target raised to $18 from $15 at RBC Capital

RBC Capital analyst Gregory Renza raised the firm’s price target on Xencor (XNCR) to $18 from $15 and...

12d ago

XNCR

Xencor price target raised to $14 from $12 at BofA

BofA raised the firm’s price target on Xencor (XNCR) to $14 from $12 and keeps a Neutral rating...

25d ago

XNCR

Xencor’s Promising Oncology and Autoimmune Advances Justify Buy Rating with $38 Price Target

Canaccord Genuity analyst John Newman has maintained their bullish stance on XNCR stock, giving a Buy rating yesterday....

13h ago

XNCR

Xencor Reports Improved Q3 2025 Financial Results

Xencor Inc. ( ($XNCR) ) has released its Q3 earnings. Here is a breakdown of the information Xencor...

2d ago

XNCR

Xencor’s Promising Clinical Updates and Strong Efficacy Support Buy Rating

William Blair analyst Matt Phipps has maintained their bullish stance on XNCR stock, giving a Buy rating yesterday....

2d ago

XNCR

Promising Developments in Xencor’s Oncology and Autoimmune Pipelines Justify Buy Rating

TD Cowen analyst Tara Bancroft has maintained their bullish stance on XNCR stock, giving a Buy rating on...

2d ago

XNCR

Xencor Inc.’s XmAb541: A Promising Phase 1 Study in Advanced Solid Tumors

Xencor Inc. (($XNCR)) announced an update on their ongoing clinical study. Study Overview: Xencor Inc. is conducting a...

11d ago

XNCR

XNCR FAQ

What was Xencor Inc’s price range in the past 12 months?

Xencor Inc lowest stock price was $6.92 and its highest was $27.24 in the past 12 months.

What is Xencor Inc’s market cap?

Xencor Inc’s market cap is $1.02B.

When is Xencor Inc’s upcoming earnings report date?

Xencor Inc’s upcoming earnings report date is Mar 04, 2026 which is in 116 days.

How were Xencor Inc’s earnings last quarter?

Xencor Inc released its earnings results on Nov 05, 2025. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.689 by $0.609.

Is Xencor Inc overvalued?

According to Wall Street analysts Xencor Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Xencor Inc pay dividends?

Xencor Inc does not currently pay dividends.

What is Xencor Inc’s EPS estimate?

Xencor Inc’s EPS estimate is -0.62.

How many shares outstanding does Xencor Inc have?

Xencor Inc has 71,323,044 shares outstanding.

What happened to Xencor Inc’s price movement after its last earnings report?

Xencor Inc reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.689. Following the earnings report the stock price went down -2.575%.

Which hedge fund is a major shareholder of Xencor Inc?

Currently, no hedge funds are holding shares in XNCR

Xencor Stock Smart Score

Outperform

Fundamentals

Return on Equity

-19.61%

Trailing 12-Months

Asset Growth

4.62%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Xencor Inc

Xencor, Inc. is a biopharmaceutical company focused on the development of engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. The company utilizes its proprietary XmAb technology platform to create novel therapeutics that enhance the efficacy and safety of antibody-based treatments. Xencor's pipeline includes multiple drug candidates that are in various stages of clinical development, targeting significant unmet medical needs in oncology and other therapeutic areas.

Xencor (XNCR) Earnings & Revenues

Historic Earnings Reports

XNCR Stock 12 Month Forecast

Average Price Target

$24.00

▲(71.43% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","24":"$24","43":"$43","14.5":"$14.5","33.5":"$33.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$42.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$24.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,14.5,24,33.5,43],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.71,16.80923076923077,18.908461538461538,21.00769230769231,23.106923076923078,25.206153846153846,27.305384615384618,29.404615384615386,31.503846153846155,33.60307692307693,35.70230769230769,37.80153846153846,39.90076923076923,{"y":42,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.71,15.424615384615386,16.13923076923077,16.853846153846156,17.568461538461538,18.283076923076923,18.997692307692308,19.712307692307693,20.426923076923078,21.14153846153846,21.856153846153845,22.57076923076923,23.285384615384615,{"y":24,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.71,14.040000000000001,13.370000000000001,12.700000000000001,12.030000000000001,11.360000000000001,10.690000000000001,10.02,9.350000000000001,8.68,8.010000000000002,7.340000000000001,6.67,{"y":6,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.26,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.84,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.98,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.28,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.36,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.69,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.86,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.58,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.07,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.98,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.55,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.83,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.71,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >